Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-blind, Randomised, Comparative Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Study of RPH-035 Versus Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

NCT07597668 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT07597668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07597668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-blind, Randomised, Comparative Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Study of RPH-035 Versus Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
Lead sponsor
R-Pharm
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 16, 2025
Completion date
November 24, 2027
Enrollment
180 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis